596817-06-0

Basic information

• Product Name: 2-Pyrrolidinecarbonitrile,1-(chloroacetyl)-4-fluoro-,(2S,4S)-
• Synonyms: 2-Pyrrolidinecarbonitrile,1-(chloroacetyl)-4-fluoro-,(2S,4S)-;(2S,4S)-1-(2-chloroacetyl)-4-fluoropyrrolidine-2-carbonitrile;2-Pyrrolidinecarbonitrile, 1-(2-chloroacetyl)-4-fluoro-, (2S,4S)-
• CAS NO: 596817-06-0
• Molecular Formula: C₇H₈ClFN₂O
• Molecular Weight: 190.6026232
• Mol File: 596817-06-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Pyrrolidinecarbonitrile,1-(chloroacetyl)-4-fluoro-,(2S,4S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyrrolidinecarbonitrile,1-(chloroacetyl)-4-fluoro-,(2S,4S)-(596817-06-0)
• EPA Substance Registry System: 2-Pyrrolidinecarbonitrile,1-(chloroacetyl)-4-fluoro-,(2S,4S)-(596817-06-0)

Safety Data

• Hazardous Substances Data: 596817-06-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
2-Pyrrolidinecarbonitrile,1-(chloroacetyl)-4-fluoro-,(2S,4S)is used as a research compound for its potential therapeutic properties. Its specific stereoisomer configuration, (2S,4S), is crucial for understanding its reactivity and biological properties, making it a valuable asset in the discovery and development of new medications.
Used in Medicinal Applications:
In the pharmaceutical industry, 2-Pyrrolidinecarbonitrile,1-(chloroacetyl)-4-fluoro-,(2S,4S)is utilized as a key intermediate in the synthesis of various drugs. Its unique structure and stereochemistry contribute to the development of novel therapeutic agents with improved efficacy and selectivity.

Upstream product

• 596817-05-9 (2S,4S)-N-chloroacetyl-4-fluoropyrrolidine-2-carboxamide 
• 79-04-9 chloroacetyl chloride 
• 426844-23-7 (2S,4S)-4-fluoropyrrolidine-2-carboxamide hydrochloride 
• 483366-11-6 (2S,4S)-4-fluoropyrrolidine-2-carbonitrile; 4-methylbenzene-1-sulfonic acid 
• 874987-63-0 (2S,4S)-4-fluoropyrrolidine-2-carbonitrile p-methylbenzenesulfonate 
• 483366-10-5 (2S,4S)-4-fluoropyrrolidine-2-carbonitrile 
• 55429-66-8 trimethylsilyl (2S,4R)-N-trimethylsilyl-4-(trimethylsilyloxy)pyrrolidine-2-carboxylate 
• 1235447-48-9 trimethylsilyl (2S,4R)-N-(chloroacetyl)-4-(trimethylsilyloxy)-pyrrolidine-2-carboxylate 
• 1235447-49-0 (2S,4R)-N-chloroacetyl-4-hydroxyproline 
• 426844-76-0 tert-butyl (2S,4S)-2-cyano-4-fluoropyrrolidine-1-carboxylate 
• 51-35-4 4-hydroxyproline 
• 426844-22-6 tert-butyl (2S,4S)-2-carbamoyl-4-fluoropyrrolidine-1-carboxylate 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 203866-13-1 (2S,4S)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid 

Downstream Products

• 929105-76-0 C₁₉H₂₀FN₅O 
• 929105-70-4 C₁₉H₁₉F₂N₅O 
• 929105-74-8 C₁₉H₁₉F₂N₅O 
• 929106-01-4 C₁₉H₁₈F₃N₅O 
• 929105-75-9 C₁₉H₁₉ClFN₅O 
• 929105-77-1 C₁₉H₁₉ClFN₅O 
• 929105-73-7 C₂₀H₁₉F₄N₅O 
• 929105-66-8 C₂₀H₁₉F₄N₅O 
• 929105-58-8 C₂₀H₂₃FN₄O₂ 
• 929105-59-9 C₂₁H₂₅FN₄O₃ 
• 929105-51-1 C₁₉H₂₂FN₅O₂ 
• 929105-53-3 C₂₀H₂₄FN₅O₂ 
• 929105-52-2 C₂₂H₂₆FN₅O₂ 
• 929105-72-6 C₁₉H₂₀FN₅O 

Relevant articles and documents

PYRROLIDINE AND PIPERIDINE COMPOUNDS

The present technology provides pyrrolidine and piperidine compounds or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. In particular, said compounds may be usefully applied in the treatment and prevention of FAP-mediated diseases.

West request acid bei geleg sandbank and intermediate preparation method

The invention relates to a preparation method of besigliptin and its intermediate, and concretely relates to a preparation method of an azadicyclic compound besigliptin and its key intermediate. The preparation method comprises the following steps: carrying out step a, step b and step c to prepare the key intermediate compound of formula VII, carryin gout isomer resolution and protective group removal on the compound of formula VII to obtain a compound of formula XV, coupling the compound of formula XV with the compound of formula XIII, and salifying to form a target compound I. The preparation method has the advantages of substantial reduction of the production cost, simple production flow, yield increase, and suitableness for industrial production.

4-fluoropyrrolidine-2-carbonyl fluorides: Useful synthons and their facile preparation with 4-tert-butyl-2,6-dimethylphenylsulfur trifluoride

4-Fluoropyrrolidine derivatives are useful in medicinal chemistry applications such as dipeptidyl peptidase IV inhibitors. As attractive synthons for these, N-protected (2S,4S)-4-fluoropyrrolidine-2-carbonyl fluorides were synthesized in high yield by double fluorination of N-protected (2S,4R)-4-hydroxyproline with 4-tert-butyl-2,6-dimethylphenylsulfur trifluoride (Fluolead). The 4-fluoropyrrolidine-2-carbonyl fluorides were converted to useful intermediates such as 4-fluoropyrrolidine-2-carboxamides, -N-methoxy-N-methylcarboxamide (Weinreb amide), -carboxylate methyl esters, and -carbonitriles in excellent yields. The crystalline N-Fmoc-cis-4- fluoropyrrolidine-2-carbonyl fluoride 2a is a particularly useful synthon due to its high yield of preparation and easy isolation as an enantiomerically pure compound by crystallization. Thus, the methodology using the synthons prepared by the stereospecific double fluorination has enabled a significant decrease in the synthetic steps needed for the preparation of the 4-fluoropyrrolidine derivatives useful for medicinal applications.

DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF

Disclosed are new dicycloazaalkane derivates represented by general formula (I), preparation processes and pharmaceutical compositions containing them, and the uses for treatment especially for dipeptidyl peptidase inhibitor (DPP-IV), in which each substitute group of general formula (I) is as defined in specification.

DIPEPTIDYL PEPTIDASE IV INHIBITORS

Described are novel compounds of the Formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol, triglyceride levels; treatment of obesity, inflammation, autoimmune diseases such as multiple sclerosis, rheumatoid arthritis; treatment and/or prophylaxis of type II diabetes. These compounds are more particularly dipeptidyl peptidase (DPP IV) inhibitors.

NOVEL 4-FLUOROPYRROLIDINE-2-CARBONYL FLUORIDE COMPOUNDS AND THEIR PREPARATIVE METHODS

Novel 4-fluoropyrrolidine-2-carbonyl fluoride compounds as useful fluorinated intermediates are disclosed. Their preparative methods are also disclosed. Useful applications of the 4-fluoropyrrolidine-2-carbonyl fluorides are shown.

Discovery of conformationally rigid 3-azabicyclo[3.1.0]hexane-derived dipeptidyl peptidase-IV inhibitors

The induction of conformationally restricted N-(aryl or heteroaryl)-3-azabicyclo[3.1.0]hexane derivatives at P2 region of compounds of 2-cyanopyrrolidine class was explored to develop novel DPP-IV inhibitors. The synthesis, structure-activity r

NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS

The present invention relates to novel processes for preparing DPP-IV inhibitors having the structure of formula I, and pharmaceutically acceptable salt thereof, which are useful for treatment of Type 2 diabetes.

Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors

Dipeptidyl peptidase IV (DPP-IV) inhibitors are promising antidiabetic drugs, and several drugs are in the developmental stage. We previously reported that the introduction of fluorine to the 4-position of 2-cyanopyrrolidine enhanced the DPP-IV inhibitory

DIPEPTIDYL PEPTIDASE IV INHIBITOR COMPOUNDS AND COMPOSITIONS

The present invention relates to dipeptidyl peptidase IV (DPP-IV) inhibitors of formula (1), pharmaceutical compositions containing them, processes for their preparation, and methods for treating disorders mediated by DPP-IV inhibition, such as diabetes, especially Type II diabetes, with them, wherein Rj is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl; R2 is hydrogen or Q-β alkyl; Y is -S(O)m, -CH2-, -CHF or CF2; R3 is hydrogen, nitrile (-CN), COOH, or an isostere of a carboxylic acid.